#United States #Salt Lake City, Utah #Nanoscope #Optogenetics #Retinal Disease

Nanoscope Therapeutics at Eyecelerator and ARVO 2025

Nanoscope Therapeutics Inc., a pioneering biotech firm focusing on restoring vision to blind patients, has recently revealed its involvement in the Eyecelerator and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings scheduled for 2025. By presenting groundbreaking results, Nanoscope aims to illustrate the effectiveness and durability of its innovative optogenetic therapy platforms designed for patients suffering from retinal degenerative diseases.

With a commitment to developing cutting-edge gene therapies, Nanoscope’s recent endeavors have particularly focused on advancing its flagship product, MCO-010. This therapy, which delivers a single injection, is the first of its kind to successfully restore vision in patients diagnosed with advanced retinitis pigmentosa (RP). The upcoming presentations are set to provide detailed insights into the significant 126-week outcomes observed in patients treated with MCO-010.

Key Highlights from the Upcoming Presentations

Dr. Samarendra Mohanty, co-founder and President of Nanoscope, expressed his enthusiasm stating, “We are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and look forward to sharing more about the positive therapeutic benefits seen in RP patients treated with our multi-characteristic opsin, or MCO, therapy.” He emphasizes that the multi-year benefits seen with MCO-010 provide meaningful options for patients facing irreversible vision loss, showcasing the potential to redefine care standards.

Eyecelerator Schedule

The Eyecelerator event will take place at the Grand Hyatt Deer Valley in Park City, Utah, on May 2, 2025. Nanoscope’s schedule includes:

• - Panel Discussion: Novel Drug Delivery Approaches for Glaucoma and Retina (12:30 PM - 1:30 PM MDT) presented by Dr. Sam Barone, Chief Medical Officer.
• - Company Showcase: Retina Gene Therapy and Novel Mechanisms of Action (1:59 PM - 2:04 PM MDT) by Dr. Jared Stephens, Vice President of Strategy and Business Development.
• - Panel: Guidance for Navigating Increasingly Complex Regulatory Pathways (3:30 PM - 4:15 PM MDT) again led by Dr. Barone.

ARVO Presentation Schedule

Following Eyecelerator, Nanoscope will also present at the ARVO conference, held from May 4 to May 8, 2025, at the Salt Palace Convention Center, Salt Lake City, Utah. Notable presentations will include:

• - Ms. Lucero Garcia presenting on the topic “Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in NHP model of geographic atrophy” on May 4, from 1:30 PM to 1:45 PM MDT.
• - Dr. SriniVas Sadda discussing “126-Week Visual Acuity Outcomes Following Mutation-Agnostic Optogenetic Therapy, MCO-010, for Retinitis Pigmentosa (RP)” on May 6, from 9:15 AM to 9:30 AM MDT.
• - Lastly, Dr. Naj Sharif will present on “Safety and Efficacy of an Image-Guided Laser-based Non-Viral Targeted Delivery of Multi-Characteristic Opsin Plasmids in African Green Monkey Retinae” on May 8, from 2:45 PM to 3:00 PM MDT.

At the ARVO conference, the Nanoscope team will be available at Booth 1337, offering an opportunity for attendees to learn more about their promising developments in vision restoration.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is at the forefront of developing mutation-agnostic therapies for individuals suffering from retinal degenerative diseases that currently lack treatment options. Following amazing results from the Phase 2b RESTORE trial (NCT04945772), the company is on track to submit a Biologics License Application (BLA) for MCO-010 aimed at treating RP in the first half of 2025. Additionally, they have successfully concluded the Phase 2 STARLIGHT trial in patients with Stargardt disease (NCT05417126) and are gearing up for the initiation of a Phase 3 trial later in 2025. With FDA Fast Track and Orphan Drug designations for both RP and Stargardt disease, Nanoscope is making significant strides in the field of ocular therapy.

The vision restored by innovative therapies like MCO-010 offers new hope for millions living with progressive vision loss. The participation at these renowned meetings marks an important step for Nanoscope as it works to bring its vision-restoring therapies closer to commercialization.